Arrowhead Pharmaceuticals, INC

Arrowhead Pharmaceuticals announced robust fiscal 2026 third quarter results, highlighting significant progress in clinical development, commercialization of REDEMPLO, and strategic partnerships.

Arrowhead Pharmaceuticals, Inc. announced the appointment of Dr. Matt Cohen as a new director, effective June 12, 2026, bringing over 25 years of healthcare investment experience.

Arrowhead Pharmaceuticals announced its fiscal 2026 second quarter results, highlighting strong commercial execution for REDEMPLO and advancements in its R&D pipeline.

Arrowhead Pharmaceuticals announced robust fiscal first quarter 2026 results, driven by the U.S. launch of REDEMPLO and significant partnership milestones.

Arrowhead Pharmaceuticals, Inc. has issued $775 million in 0.00% Convertible Senior Notes due 2032, alongside capped call transactions to manage potential share dilution.

Arrowhead Pharmaceuticals priced concurrent public offerings of $625 million in convertible senior notes and 3.1 million shares of common stock, including pre-funded warrants, to raise approximately $897.9 million in net proceeds for general corporate purposes.

Arrowhead Pharmaceuticals reports a significant revenue decrease in its second fiscal quarter of 2026 compared to the prior year, primarily due to lower Sarepta collaboration revenue, while advancing its pipeline with new clinical trial initiations and regulatory milestones.

Arrowhead Pharmaceuticals reports a significant financial turnaround in Q1 2026, driven by key regulatory approvals, substantial milestone payments, and a new collaboration with Novartis, alongside a strengthened balance sheet.

Arrowhead Pharmaceuticals reported a significant financial turnaround and pipeline advancements, driven by its Sarepta collaboration and key regulatory progress for plozasiran.

Arrowhead Pharmaceuticals' Q2 2025 results show a significant increase in revenue and net income, primarily due to the Sarepta Therapeutics collaboration.

Arrowhead Pharmaceuticals' Q1 2025 results reveal increased R&D spending, a major collaboration with Sarepta, and progress on regulatory submissions.

Arrowhead Pharmaceuticals reported its Q3 2024 financial results, highlighting progress in its clinical pipeline and a recent $429.3 million capital raise.

Arrowhead Pharmaceuticals reports its first commercial launch of REDEMPLO for FCS, significant milestone payments from Sarepta and Novartis, and continued pipeline advancement in its latest 10-K filing.

Arrowhead Pharmaceuticals filed an amendment to its annual report, providing detailed information on corporate governance, executive compensation, and director changes, alongside significant business and financial updates.

Arrowhead Pharmaceuticals' 2024 annual report details a year of significant pipeline advancements, strategic collaborations, and financial activities, including a substantial net loss and a major financing agreement.

Director Matthew Gregory Cohen received a grant of 11,882 restricted stock units from Arrowhead Pharmaceuticals.

Director Hongbo Lu sold 2,970 shares of Arrowhead Pharmaceuticals common stock at $76.88 per share.

Arrowhead Pharmaceuticals CFO Daniel Joseph Apel sold 13,095 shares of common stock to satisfy tax obligations via a 10b5-1 plan.

Arrowhead Pharmaceuticals Chief Medical Officer James C. Hamilton sold 10,000 shares of common stock via a 10b5-1 trading plan.

Arrowhead Pharmaceuticals' Chief Medical Officer, James C. Hamilton, was granted 75,000 restricted stock units vesting over four years.

Arrowhead Pharmaceuticals' Chief Financial Officer, Daniel Joseph Apel, was granted 75,000 restricted stock units, increasing his beneficial ownership to 176,200 shares.

Arrowhead Pharmaceuticals, Inc. announced its 2026 Annual Meeting of Stockholders to be held virtually on March 19, 2026, to vote on director elections, executive compensation, an incentive plan, and auditor ratification.

Arrowhead Pharmaceuticals, Inc. announces its 2026 Annual Meeting of Stockholders, highlighting significant financial improvements, key regulatory approvals, and pipeline advancements.

Arrowhead Pharmaceuticals appoints Douglas Ingram, CEO of Sarepta Therapeutics, to its Board of Directors, effective February 6, 2025, as part of an Investor Rights Agreement.

Arrowhead Pharmaceuticals has filed a proxy statement with the SEC, signaling upcoming shareholder meetings and voting on company matters.

Arrowhead Pharmaceuticals will hold its 2025 Annual Meeting of Stockholders virtually on March 12, 2025, to vote on director elections, executive compensation, auditor ratification, and other matters.

Arrowhead Pharmaceuticals supplements its proxy statement to address concerns raised by ISS and Glass Lewis regarding the independence of director Dr. Douglass Given and announces changes to board committee assignments.

Sarepta Therapeutics has fully divested its stake in Arrowhead Pharmaceuticals through a secondary sale and a share redemption tied to a milestone payment.

Sarepta Therapeutics Investments, a subsidiary of Sarepta Therapeutics, has acquired a 9.5% stake in Arrowhead Pharmaceuticals for $325 million, formalizing a strategic collaboration and gaining board representation.

Vanguard Portfolio Management has reported a 4.53% stake in Arrowhead Pharmaceuticals Inc., holding over 6.38 million shares.

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 5.2% in Arrowhead Pharmaceuticals Inc. as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.05% of Arrowhead Pharmaceuticals Inc.'s common stock as of March 31, 2026.

Vanguard Portfolio Management has reported beneficial ownership of 5.19% of Arrowhead Pharmaceuticals Inc.'s common stock as of March 31, 2026.

The Vanguard Group filed an amended Schedule 13G for Arrowhead Pharmaceuticals Inc., reporting 0% beneficial ownership following an internal realignment.

BlackRock, Inc. has increased its beneficial ownership in Arrowhead Pharmaceuticals Inc. to 15.0% of common stock, holding over 20 million shares.